Hepatocellular carcinoma
- 1 April 1999
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 353 (9160), 1253-1257
- https://doi.org/10.1016/s0140-6736(98)09148-x
Abstract
Hepatocellular carcinoma (HCC) for most patients is a terminal complication of chronic inflammatory and fibrotic liver disease. With regrettably few exceptions, treatment is largely palliative, and long-term survival is rare. However, the major causes of HCC worldwide are known and preventable. Hepatitis B and C exist only in man; the viruses have no known non-human reservoirs. Transmission of the viruses can be interrupted by vaccination against hepatitis B virus infection and improvements in medical techniques for hepatitis C, for which no vaccine has yet been developed.This publication has 37 references indexed in Scilit:
- Long-term survival in patients with hereditary hemochromatosisGastroenterology, 1996
- Alcohol, Hepatotropic Viruses, and Hepatocellular CarcinomaAlcohol: Clinical and Experimental Research, 1995
- Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patientsGastroenterology, 1995
- Blood Supply of Early Hepatocellular CarcinomaSeminars in Liver Disease, 1995
- Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoproteinJournal of Hepatology, 1994
- Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolizationCancer, 1993
- Hepatocellular Carcinoma in CirrhoticsSeminars in Liver Disease, 1993
- Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients.American Journal of Roentgenology, 1993
- Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapyHepatology, 1992
- Natural and experimental infection of wild mallard ducks with duck hepatitis B virusJournal of General Virology, 1991